Kinoxis Therapeutics is a private, Australian-based, clinical stage biotechnology company developing first-in-class therapeutics to address the escalating demand for effective treatments for substance use disorders and social dysfunction in neurological and psychiatric disorders. Kinoxis’ development candidates are novel, small molecules that were discovered through a comprehensive medicinal chemistry and screening program at the University of Sydney. Kinoxis' lead compound KNX100 is commencing Phase 2 studies in 2024, with the first study aimed at the treatment of agitation and aggression in dementia patients, and the second study for the treatment of withdrawal symptoms in patients with opioid use disorder. The company also has an early-stage license and development collaboration in place with Boehringer Ingelheim, focused on developing novel compounds targeting the brain oxytocin system.